rocky start for alzheimers research
Last Updated : GMT 05:07:50
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
Last Updated : GMT 05:07:50
Themuslimchronicle, themuslimchronicle

In 2018

Rocky start for Alzheimer's research

Themuslimchronicle, themuslimchronicle

Themuslimchronicle, themuslimchronicleRocky start for Alzheimer's research

Alzheimer's cure
Paris - Muslimchronicle

The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Within the first three weeks, pharmaceutical giant Pfizer abandoned the costly and frustrating field of dementia drug development, and two promising treatments stumbled in patient trials.

Alzheimer's support groups are putting on a brave face, but the collective disappointment is palpable as the global cost of caring for some 50 million dementia sufferers is set to reach $1 trillion (819 billion euros) this year.

"It's very fair to say that progress is slow," David Reynolds, chief scientific officer at Alzheimer's Research UK, a charity, told AFP.

"Companies have put a lot of time, effort and money in over the last 25 years, and there haven't been any new medicines launched in this area for 16 years now."

Experts say it takes 12–15 years, on average, and more than $2 billion to develop a single drug.

According to the Alzforum website, which gathers data on candidate drugs, fewer than 300 have made it to Phase II drug efficiency trials so far.

Only five have ever been approved to treat symptoms such as memory loss associated with Alzheimer's, first identified more than 100 years ago.

With a clinical trial failure rate of over 99 percent, there is still no licenced drug that slows the condition's progression, or cures it.

Today, about 100 candidate dementia drugs are enrolled in trials, compared to over 1,000 for cancer, according to Reynolds.

One reason is that "pharmaceutical companies ultimately are companies. They are beholden to their investors," he said.

"A return on investment is really: How much time and money do you put into getting a new medicine versus how much money can you make once you've actually got it? In this area, success has been very difficult to come by."

- Mysterious brain -

The stakes are high.

According to the World Health Organization (WHO), some 10 million people per year are diagnosed with dementia, with Alzheimer's disease accounting for about two-thirds of cases.

By 2030, the number of sufferers is projected to reach 82 million globally, and by 2050 some 152 million.

The medical, patient-care, and economic costs are enormous.

A heavy burden falls on family members, the majority of care providers worldwide. Many have to give up their jobs.

Alzheimer's affects mainly older people -- about one in four over-85s is a sufferer. And numbers have soared as lifespans have lengthened thanks to medical advances in other fields.

With cardiovascular disease and cancer the biggest killers in the 1960s and '70s, that is where most of the research money went.

"In dementia, that investment wasn't there. So the amount of knowledge... about the disease is at a much, much earlier stage, and arguably the brain is a much more complicated organ" than the heart, said Reynolds.

To this day, scientists don't know exactly what causes Alzheimer's, leaving drug developers stumped.

On January 6, Pfizer announced an end to its "discovery and early development efforts" for Alzheimer's and Parkinson's dementia drugs.

Two days later, Danish company Lundbeck reported its idalopirdine compound did not "decrease cognitive loss" in patients, and on January 12, biotech firm Axovant announced the end of the road for its offering, intepirdine.

- Slow, but not backwards -

Experts say every failure of a drug reveals something new about Alzheimer's disease, which is thought to be associated with a buildup of protein "plaques", and "tangles" in the brain.

One important recent realisation was that an effective treatment may have to begin long before symptoms appear as protein build-up likely starts decades before disease sets in.

This, in itself, presents a research challenge.

"How do you find these patients?" when they are in middle age and symptom-free, explained French neurology professor Bruno Dubois. "How long do you treat them?"

Drugs in development today are targeting several tracks.

Some use antibodies to mop up proteins in circulation, or enzymes to inhibit their production.

Another experimental approach is vaccination: training the body to produce its own antibodies to attack disease-causing proteins.

"We are not moving backwards," insisted Reynolds.

Yet, he was "by no means certain" that a goal set by the G8 in 2013 to develop a cure or treatment for dementia by 2025 can be met.

"Even knowing the obstacles, we have never been as optimistic as we are today," added James Hendrix, a director at the US-based Alzheimer's Association, one of several non-profit research funders.

"We will not slow down in our fight against this terrible disease," he vowed.

"We are steadfastly committed to both advocating for further increased federal funding for Alzheimer's and dementia research, and increasing our own level of research funding to get us to where we ultimately need to be -- a world without Alzheimer's disease."

themuslimchronicle
themuslimchronicle

GMT 08:57 2018 Tuesday ,23 January

To 'eternal style' of late Alaia

GMT 09:02 2018 Monday ,22 January

Uggs, pigs and tartan

GMT 07:43 2018 Sunday ,21 January

Gardiner announces freelance details

GMT 06:39 2018 Thursday ,18 January

designer Jones quits Louis Vuitton

GMT 08:08 2018 Wednesday ,17 January

Pretty dresses are no longer just

GMT 11:22 2018 Tuesday ,16 January

Lacobella appoints 5th House PR

GMT 08:22 2018 Monday ,15 January

Dolce & Gabbana's royal flush wows

GMT 08:30 2018 Sunday ,14 January

The Dovetail Agency launches events
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

rocky start for alzheimers research rocky start for alzheimers research

 



Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicleSkincare PR Performance Full Year 2017

GMT 09:06 2018 Monday ,22 January

Skincare PR Performance Full Year 2017
Themuslimchronicle, themuslimchronicleEurope brings on charm and blue skies

GMT 08:37 2018 Tuesday ,23 January

Europe brings on charm and blue skies
Themuslimchronicle, themuslimchronicleModern colorful bedroom renovation

GMT 10:57 2017 Thursday ,21 December

Modern colorful bedroom renovation
Themuslimchronicle, themuslimchroniclePuigdemont candidate for Catalan president

GMT 08:25 2018 Tuesday ,23 January

Puigdemont candidate for Catalan president
Themuslimchronicle, themuslimchronicleAmazon to open first cashierless shop

GMT 08:31 2018 Tuesday ,23 January

Amazon to open first cashierless shop
Themuslimchronicle, themuslimchronicleThe Rake announces editorial updates

GMT 08:20 2018 Wednesday ,17 January

The Rake announces editorial updates
Themuslimchronicle, themuslimchronicleAirbus to get '10 years of visibility'

GMT 08:39 2018 Monday ,22 January

Airbus to get '10 years of visibility'
Themuslimchronicle, themuslimchronicleFor the Variety of Interior Design Styles

GMT 10:46 2017 Tuesday ,19 December

For the Variety of Interior Design Styles
Themuslimchronicle, themuslimchronicleUS Christian tourists see deep meaning

GMT 08:00 2018 Monday ,22 January

US Christian tourists see deep meaning
Themuslimchronicle, themuslimchronicleWENN appoints entertainment journalist

GMT 09:07 2018 Monday ,22 January

WENN appoints entertainment journalist

GMT 10:58 2017 Monday ,18 December

Haftar describes Skhirat as expired agreement

GMT 20:34 2017 Wednesday ,15 March

Renault 'formally denies' cheating in emissions tests

GMT 08:53 2017 Wednesday ,20 December

Sausage makers fight 'cartel' fine

GMT 18:27 2017 Friday ,21 April

ARCO condemns targeting of ERC convoy in Somalia

GMT 10:49 2016 Saturday ,20 August

Lyft move to sell itself got little traction

GMT 08:25 2015 Monday ,19 October

Lorenzo closes world MotoGP title gap on Rossi

GMT 08:11 2018 Tuesday ,09 January

'Blackout' on Globes red carpet

GMT 01:45 2016 Friday ,09 December

6.5-Magnitude earthquake hits Indonesia

GMT 09:21 2017 Sunday ,19 March

Rock n' Roll legend Chuck Berry dead at 90

GMT 16:45 2017 Friday ,13 October

Uber files appeal against London ban

GMT 12:24 2017 Friday ,01 December

Bahrain press headlines

GMT 07:55 2017 Monday ,23 October

Einstein's theory of happy living emerges

GMT 16:31 2017 Wednesday ,27 September

EBRD to boost local currency lending in Morocco

GMT 09:31 2017 Friday ,17 November

Pussy Riot's prison ordeal relived in London art show

GMT 06:59 2017 Monday ,18 December

Brazilian star Kaka announces retirement

GMT 16:02 2017 Tuesday ,31 October

Asian markets largely quiet on back of US retreat

GMT 11:19 2017 Saturday ,25 November

Smith defies England as Australia fight back in Ashes

GMT 09:17 2017 Monday ,04 December

Cricketers vomiting after fielding in smoggy Delhi

GMT 09:13 2017 Saturday ,02 December

Lewd comments cause YouTube to pull videos of children
Themuslimchronicle, themuslimchronicle
Themuslimchronicle, themuslimchronicle
 
 Themuslimchronicle Facebook,themuslimchronicle facebook  Themuslimchronicle Twitter,themuslimchronicle twitter Themuslimchronicle Rss,themuslimchronicle rss  Themuslimchronicle Youtube,themuslimchronicle youtube  Themuslimchronicle Youtube,themuslimchronicle youtube
muslimchronicle muslimchronicle muslimchronicle muslimchronicle
themuslimchronicle themuslimchronicle themuslimchronicle
themuslimchronicle
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
themuslimchronicle, themuslimchronicle, themuslimchronicle